Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Rises By 6.9%

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Get Free Report) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 20,100 shares, a growth of 6.9% from the March 31st total of 18,800 shares. Based on an average trading volume of 5,600 shares, the days-to-cover ratio is presently 3.6 days. Currently, 0.2% of the company's shares are sold short.

Anebulo Pharmaceuticals Stock Performance

Shares of NASDAQ:ANEB traded up $0.15 during midday trading on Tuesday, hitting $2.90. 18,500 shares of the stock traded hands, compared to its average volume of 5,432. Anebulo Pharmaceuticals has a one year low of $1.62 and a one year high of $4.05. The business's 50 day moving average is $2.75 and its two-hundred day moving average is $2.49.

Anebulo Pharmaceuticals (NASDAQ:ANEB - Get Free Report) last issued its quarterly earnings data on Tuesday, February 13th. The company reported ($0.11) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.11). As a group, equities analysts anticipate that Anebulo Pharmaceuticals will post -0.47 EPS for the current year.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.